The Latest on Life Science Innovations

The California Biotechnology Foundation is committed to keeping you up to date about the latest breakthroughs in biotech treatments and the impact of one of California’s largest industries in the state and beyond. This newsletter edition, as of September 23, 2026, brings you updates directly from the forefront of medical innovation. Among the notable advancements featured are:

• An experimental CAR T-cell therapy targeting the GPC3 protein eliminated signs of metastatic liver cancer in a 3-year-old patient after two doses, with the child remaining cancer-free one year later.

• The FDA approved Ultragenyx’s Fayuvi, a one-time gene therapy and the first approved treatment for children with Sanfilippo syndrome type A, a rare genetic disease that progressively damages the brain and nervous system.

• Eli Lilly’s brenipatide, a drug that targets two hormones involved in metabolism, showed promising early results and is now being studied in late-stage trials for major depression and alcohol use disorder.